Quantum BioPharma Submits Its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in ...

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for ...

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in ...

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary,…

Where do you want to be be treated?. What happens when you stop

We have been discussing Natalizumab in the past few days, each one of these dots is an NHS trust in England where people with MS are treated. There looks like there is one outlier…. My work i…

Quantum BioPharma Submits MS Drug Candidate to UK’s ILAP Program

Quantum BioPharma Ltd. (NASDAQ: QNTM) has taken a pivotal step in the development of its multiple sclerosis (MS) treatment by submitting its drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program. This submission underscores the company’s commitment to leveraging strategic regulatory pathways to expedite the clinical advancement and patient access to innovative treatments. The ILAP pr…